Form 4: Rhythm Pharmaceuticals Director Camille L. Bedrosian Reports Stock Option and Restricted Stock Unit Grants

Director Camille L. Bedrosian reports the acquisition of stock options and restricted stock units in Rhythm Pharmaceuticals.

Summary

• Camille L. Bedrosian, a director of Rhythm Pharmaceuticals, reported the acquisition of stock options and restricted stock units on June 18, 2024.
• The stock options grant consists of 14,000 options with an exercise price of $41.39.
• These options vest fully upon the earlier of June 18, 2025, or the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to continued service.
• Additionally, 4,000 restricted stock units (RSUs) were granted, each representing a contingent right to receive one share of Rhythm Pharmaceuticals common stock.
• These RSUs also vest fully upon the earlier of June 18, 2025, or the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to continued service.
• Following these transactions, Bedrosian directly owns 14,000 stock options and 4,000 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSU grants, which is generally a positive sign of aligning management with shareholder interests, but not significantly impactful on its own.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule, contingent on continued service, incentivizes the director to remain with the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's securities. This allows investors to monitor insider activity, which can provide insights into management's perspective on the company's value and prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, used to align management's interests with shareholder value.
• Vesting schedules tied to continued service are standard practice to incentivize long-term commitment.
• The size of the grant (14,000 options and 4,000 RSUs) would need to be compared to grants made to directors at comparable pharmaceutical companies to assess its relative significance.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates